Curio Wealth’s Citius Pharmaceuticals CTXR Stock Holding History

Curio Wealth’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,000	Closed	-$1.8K	–	323
2026 Q1	$1.8K	Hold	2,000	–	–	﹤0.01%	324
2025 Q4	$1.6K	Buy	+2,000	New	+$2.5K	﹤0.01%	348

Other funds holding CTXR

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MFS

Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

Curio Wealth's CTXR Position: Q2 2026 in Review

Curio Wealth sold out of Citius Pharmaceuticals (CTXR) in Q2 2026, closing a stake of 2,000 shares — an estimated $1.8K sold.

Curio Wealth first reported a position in CTXR in Q4 2025 and held it in 2 quarters. The position peaked at $1.8K in Q1 2026. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

Curio Wealth reported no remaining Citius Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Curio Wealth sold 2,000 Citius Pharmaceuticals shares in Q2 2026, an estimated $1.8K.
Curio Wealth first reported a position in Citius Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Curio Wealth's Citius Pharmaceuticals position peaked at $1.8K in Q1 2026.
43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Curio Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.